Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256044 | 0.87 | GRM5 (0.46) | GRM5MAPK14ASIC3ALDH1A1 | |
| SCHEMBL3669473 | 0.85 | ALDH1A1 (0.37) | GRM5ALDH1A1HPGD | |
| SCHEMBL9234412 | 0.79 | GRM5 (0.47) | GRM5 | |
| SCHEMBL17955540 | 0.79 | GRM5 (0.44) | GRM5MAPK14ASIC3 | |
| SCHEMBL103337 | 0.76 | GRM5 (0.42) | GRM5MAPK14ASIC3 | |
| SCHEMBL8890442 | 0.76 | GABRP (0.38) | GRM5ALDH1A1HPGD | |
| SCHEMBL9949090 | 0.71 | GRM5 (0.37) | GRM5ALDH1A1HPGD | |
| SCHEMBL102810 | 0.70 | GRM5 (0.45) | GRM5ASIC3ALDH1A1HPGD | |
| SCHEMBL31036128 | 0.70 | GRM5 (0.45) | GRM5ASIC3ALDH1A1HPGD | |
| SCHEMBL15536945 | 0.70 | GRIK1 (0.43) | GRM5ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480554-B1 | MACROCYCLIC INHIBITORS OF JAK | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8318764-B2 | Macrocyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2012-11-27 | — | — | US | disclosed |
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAHANGIR ALAM | 2011-03-24 | — | — | US | disclosed |
| US-6028087-A | Platelet aggregation inhibiting compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0677043-A4 | — | — | 1995-11-22 | — | — | EP | disclosed |
| EP-0677043-A1 | PLATELET AGGREGATION INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1994014775-A1 | PLATELET AGGREGATION INHIBITING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071179-A1 | MACROCYCLIC INHIBITORS OF JAK | JAK2, JAK1, JAK3 | GRM5 4171/4885MAPK14 392/4885ASIC3 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.